Genus Prime (532425)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 1,950% shows some revenue momentum, though from a very low base with latest quarter sales of only ₹1 Cr.
• Book value of ₹17.63 provides a tangible asset reference; the P/B of 1.49 is not an extreme speculative multiple.
• ROE of 8.83% is positive, so the company is not entirely destroying equity.
• Market cap of ₹39 Cr is small enough that even modest absolute profit improvement could have a large percentage effect if actually delivered.

Concerns

• P/E of 62.27 with latest quarter net profit of ₹0 Cr and profit growth of 0% means the price already assumes earnings that do not exist.
• ROCE of -0.06% and Piotroski F-Score of 3/9 indicate weak operational and financial health.
• No dividend, unknown promoter holding, and insufficient FairStock data make transparency a major issue.
• Commodity chemicals is a cyclical, price-taking industry with no visible moat or pricing power.

AI Analysis

When I look at Genus Prime, I see a ₹39 crore micro-cap in a commodity chemicals business, and my first instinct is caution. The price is ₹26.28, which looks affordable, but value is not the same as price. The trailing P/E of 62.27 is very expensive for a company whose latest quarter reported sales of just ₹1 crore and net profit of ₹0 crore. Profit growth is flat at 0%, while sales growth of 1,950% sounds dramatic, but percentages from a tiny base can deceive; one crore rupees in a quarter is nothing in the chemicals industry. Benjamin Graham taught me to focus on financial health. The Piotroski F-Score of 3/9 is poor, and ROCE of -0.06% means the company is not earning a positive return on its capital. ROE of 8.83% is modest, not enough to justify a 62 times earnings multiple. At ₹17.63 book value, the shares trade at 1.49 times book, so I am paying a premium for a business that is not currently generating real earnings. There is no dividend to give me any return while I wait. I also have a serious data problem. Promoter holding is not available, debt/equity is not available, and the FairStock score says insufficient data. As an investor, I cannot value what I cannot understand. The PEG ratio of 0.03 appears attractive, but it means nothing when profit growth is zero. Commodity chemicals is a cyclical, price-taking industry with no moat. Without pricing power, margins can disappear quickly. This is not a business that offers a margin of safety; it is a speculative stock, not an investment. I would rather watch from the sidelines until the finances improve and the numbers give me something concrete to value.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer